Did it tell you the PPS was going drop as much as it did? Does it tell you that the analysts covering the stock don't know how to predict things? Does it tell you that investing in biotech is a #$%$ shoot at best and you just need to be luck rather than good. I doubt it.
Some MM has paid Zacks to put out a very timely article about ARNA possibly beating earnings estimates for Q2. Why you ask would they feel the need to do that? Well this is my theory. The MM know that Jack will have to reveal bad news about declining sales of his Belviq drug going forward and they badly want to continue shorting this stock down to the $2's but in order to get the most bang for their buck, they want people to think there maybe a reason to buy the stock when they really want to short it more. They get someone like Zacks to publish a worthless article in hopes that a few day trading suckers will buy in for a quick pop. When they do, they shorts will pounce prior to, during and after the CC and make another killing as this drops further.
Then it's guidance time! We'll see if they step up to the plate or not. My bet is that they will disappoint even with good news. They are just getting no positive pub to take this higher and to boot sales will slow later in the year as the plus size people hand in their bathing mo-mo's for sweat pants for 9 more months.
Their look ahead has to suck! The obesity drug is dying and will fall below VVUS in a few more weeks. They should just sell and get out and start all over with bath oils or something like that.
When you listen to the CC tomorrow, please put on the Doors famous hit...This is the end and you are allowed one funky cigarette while doing so. Toke it slow...It may be your last?
VVUS is done now but ARNA is trying to catch them as well. ARNA should sell to OREX and use cash for R&D on pipeline if it's that good and VVUS should close the doors and go home. OREX wins and uses money to start up in EU.
In Europe they would be the only game in town! In the US look for either ARNA or VVUS to close up the shop, take their looses and go home. This time next year there will only be two of the current suppliers here in the US. Both are losing share and money and both have other drugs they can market. ARNA's pipeline needs cash to further their studies and Belviq is dying off fast. They should just sell to OREX and use the 500 million for R&D.
It's very hard to be positive about any bio tech stocks these days. If this leak or rumor is true, don't you think some of the bigger players would verify it and if found to be accurate, they would be buying a lot under the radar. That's not happening so how true can it be? Makes sense doesn't it. Anyone can write what they want but if it can be backed it with fact and strong buying than it's no longer a rumor. Until then, just a ........
Ok-time to chime- via euro-newswire rueters- word on the street is to expect weight loss drug-mys- to be on the market in as many as 10 eu countries by eom sep 15-finialization of pending dist contracts and country approval procedures ----------looks to me like they are going this one alone ----------there is only one lawsuit pending on the dockets of federal courts- if you know of more please give us the docket# and court it was filed in- and that is the patent infringement on stopping generic mfg in us. ---with 2 patents in place and prior court decisions on the books this is an easy settlement or court toss out. yes there is a leveling out of scripts but with mys. Roll out don"t wait to long to weigh in before news becomes official-my bet is they have or are close with takeda on plan to fund long study and that they have cut production costs and established dist fees to offset their portion. We then will be back to the numbers and based on existing n. America and 10 euro countries this is a win-win everywhere. This is going back to $8 plus vary soon. Dont be caught in the up tick thursday/friday. now is better look at option contracts
a target of $11.33 continue to get paid when the stock is priced so low currently? The price obviously reflects full European roll out and a much stronger launch in the US. Since both revenue sources are not even close to what they thought, shouldn't they lower their targets to something more realistic for the time being? How do people put faith in what they say when what they say makes no sense. They don't want to lower there target for some reason! They must know that Europe is a done deal in concept but that it will take longer than expected. If they thought it was not going to happen then they would reduce their numbers. Just saying!
Earnings will be negative, sales growth is stagnating, no resolution with Takeda, lawsuits still open and no partner news in Europe. Secondary coming down to $4.00. Well at least that's what I though I heard.
In just 5 days. They propped it up to do the secondary to get their cash. Not that they have it the longs have mysteriously stopped buying and are now getting out in an orderly fashion. You should too. $100 is right around the corner which will inflict max pain on short term longs.
I am not suggesting anything. I am stating my observation from past history. Look at the post just before mine today. SURPRISE, an upgrade from Zacks!!! Did I call it or what. It's all part of the game man. Just gotta learn how to play.